Point72 Asset Management L.P. lessened its position in shares of Sanofi SA (NYSE:SNY) by 25.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 112,500 shares of the company’s stock after selling 37,500 shares during the period. Point72 Asset Management L.P.’s holdings in Sanofi were worth $4,501,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently modified their holdings of the company. Private Capital Group LLC lifted its holdings in shares of Sanofi by 271.3% during the 1st quarter. Private Capital Group LLC now owns 2,577 shares of the company’s stock worth $103,000 after acquiring an additional 1,883 shares during the period. Squar Milner Financial Services LLC bought a new stake in shares of Sanofi during the 2nd quarter worth approximately $169,000. IHT Wealth Management LLC lifted its holdings in shares of Sanofi by 246.6% during the 1st quarter. IHT Wealth Management LLC now owns 4,239 shares of the company’s stock worth $167,000 after acquiring an additional 3,016 shares during the period. SVA Plumb Wealth Management LLC bought a new stake in shares of Sanofi during the 1st quarter worth approximately $218,000. Finally, GWM Advisors LLC bought a new stake in shares of Sanofi during the 1st quarter worth approximately $201,000. 7.54% of the stock is owned by institutional investors.
A number of analysts have recently weighed in on SNY shares. Citigroup raised shares of Sanofi from a “neutral” rating to a “buy” rating in a report on Friday, August 10th. ValuEngine downgraded shares of Sanofi from a “sell” rating to a “strong sell” rating in a report on Saturday, June 2nd. Argus upped their price target on shares of Sanofi from $46.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, August 24th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a report on Tuesday, July 31st. Finally, Bank of America raised shares of Sanofi from a “neutral” rating to a “buy” rating and set a $55.00 price target for the company in a report on Monday, September 10th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $49.00.
SNY stock opened at $43.90 on Thursday. The company has a market cap of $110.26 billion, a P/E ratio of 13.96, a P/E/G ratio of 2.36 and a beta of 0.85. Sanofi SA has a 1 year low of $37.43 and a 1 year high of $50.65. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40.
Sanofi (NYSE:SNY) last released its quarterly earnings data on Tuesday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.72 by $0.02. The business had revenue of $8.18 billion during the quarter, compared to analysts’ expectations of $8.27 billion. Sanofi had a net margin of 10.29% and a return on equity of 23.77%. The firm’s quarterly revenue was down 5.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.35 EPS. research analysts expect that Sanofi SA will post 3.14 earnings per share for the current fiscal year.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Read More: Google Finance Portfolio Tips and Tricks
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.